When the FDA resolved legal hurdles to the 505(b)(2) approval pathway in 2003, providing a practical alternative route for drug development, Ken Phelps and Ruth Stevens founded Camargo Pharmaceutical Services to help companies gain approval under 505(b)(2). Camargo will be celebrating both events in booth 410 at the DIA Annual Meeting in Boston, June 23-27.   “FDA approvals under 505(b)(2) have risen every year since 2003 because it offers a faster and less costly process that permits developers...